GCGR and type 2 diabetes mellitus: The relative increase in liver TAG levels compared to mice treated with I501 is in good agreement with previous findings in rodents and individuals with type 2 diabetes [21, 41], and may be caused by inhibition of GCGR signalling, as it is known that glucagon increases hepatic lipolysis and oxidation of fatty acids [42, 43].